On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated ...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product ...

Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...

Viatris (VTRS) stock gains as the FDA OK its generic Iron Sucrose Injection targeting Venofer marketed by Daiichi Sankyo (DSKYF) (DSNKY) and Vifor. Read more here.

Generic versions of CSL’s iron replacement therapy Venofer have arrived in the U.S. after a yearslong wait. | Generic ...

Viatris receives US FDA approval for generic iron sucrose injection to treat IDA in chronic kidney disease: Pittsburgh Tuesday, August 12, 2025, 18:00 Hrs [IST] Viatris Inc., a gl ...

Investing.com -- Viatris Inc (NASDAQ: VTRS) stock rose 2.6% following the U.S. Food and Drug Administration’s approval of the company’s Iron Sucrose Injection, USP, the first generic version of ...

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron ...

US generics major Viatris has won US Food and Drug Administration (FDA) approval for iron sucrose injection, USP, an ...

Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.

Among Indian generics makers, Iron Sucrose had been considered a key pipeline product for Dr. Reddy’s Laboratories and ...

Q2 2025 Earnings Call Transcript August 7, 2025 Viatris Inc. beats earnings expectations. Reported EPS is $0.62, expectations ...